Abbott

OverviewSuggest Edit

Abbott Laboratories is a healthcare company that develops, manufactures, and sells healthcare products. It specializes in diagnostics, medical devices, nutritionals, and branded generic medicines. The company offers glucose monitoring, blood and plasma screening, adult nutrition, pediatric nutrition, remote heart failure monitoring, diagnostic testing, chronic pain solutions, and other services.
TypePublic
Founded1888
HQLake Bluff, IL, US
Websiteabbott.com
Employee Ratings3.9
Overall CultureB+

Latest Updates

Employees (est.) (Dec 2021)113,000(+4%)
Job Openings2,964
Revenue (FY, 2021)$43.1 B(+25%)
Share Price (Aug 2022)$109.5
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Abbott

Robert B. Ford

Robert B. Ford

Chairman and Chief Executive Officer
Robert E. Funck

Robert E. Funck

Executive Vice President, Finance and Chief Financial Officer
Hubert L. Allen

Hubert L. Allen

Executive Vice President, General Counsel and Secretary
Lisa D. Earnhardt

Lisa D. Earnhardt

Executive Vice President, Medical Devices
John F. Ginascol

John F. Ginascol

Executive Vice President, Core Diagnostics
Joseph Manning

Joseph Manning

Executive Vice President, Nutritional Products
Show more

Abbott Office Locations

Abbott has offices in Lake Bluff, Alameda, Austin, Des Plaines and in 126 other locations
Lake Bluff, IL, US (HQ)
100 Abbott Park Rd
Alameda, CA, US
1360 S Loop Rd
Austin, TX, US
8701 Bee Cave Rd Bldg 2
Des Plaines, IL, US
1300 E Touhy Ave
Lake Forest, IL, US
100 S Saunders Rd
Lake Forest, IL, US
675 N Field Dr
Show all (145)

Abbott Financials and Metrics

Abbott Revenue

Embed Graph
View revenue for all periods
Abbott's revenue was reported to be $43.08 b in FY, 2021 which is a 24.5% increase from the previous period.
USD

Revenue (Q1, 2022)

11.9b

Gross profit (Q1, 2022)

6.9b

Gross profit margin (Q1, 2022), %

58.1%

Net income (Q1, 2022)

2.4b

EBIT (Q1, 2022)

2.9b

Market capitalization (1-Aug-2022)

191.8b

Closing stock price (1-Aug-2022)

109.5

Cash (31-Mar-2022)

7.7b

EV

201.2b
Abbott's current market capitalization is $191.8 b.
Annual
USDFY, 2019FY, 2020FY, 2021

Revenue

31.9b34.6b43.1b

Revenue growth, %

4%8%24%

Cost of goods sold

13.2b15.0b18.5b

Gross profit

18.7b19.6b24.5b
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

7.5b8.0b8.1b7.7b7.3b8.9b10.5b10.2b10.9b11.9b

Cost of goods sold

3.2b3.3b3.4b3.3b3.3b4.0b4.4b4.9b4.4b5.0b

Gross profit

4.4b4.7b4.7b4.4b4.1b4.9b6.1b5.3b6.5b6.9b

Gross profit Margin, %

58%59%58%58%55%55%58%52%60%58%
Annual
USDFY, 2010FY, 2019FY, 2020FY, 2021

Cash

3.6b3.9b6.8b9.8b

Accounts Receivable

7.2b5.4b6.4b6.5b

Prepaid Expenses

1.5b

Inventories

3.2b4.3b5.0b5.2b
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

3.4b4.8b4.5b8.1b8.7b9.3b7.7b

Accounts Receivable

5.3b5.1b5.6b6.1b6.1b6.4b7.2b

Inventories

4.6b5.2b5.2b5.4b5.4b5.3b5.7b

Current Assets

15.5b17.2b17.4b21.8b22.6b23.5b23.4b
Annual
USDFY, 2019FY, 2020FY, 2021

Net Income

3.7b4.5b7.1b

Depreciation and Amortization

3.0b3.3b3.5b

Inventories

(593.0m)(493.0m)(456.0m)

Accounts Payable

1.8b1.3b
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

564.0m1.1b2.3b1.8b3.0b5.1b2.4b

Depreciation and Amortization

828.0m1.7b2.5b934.0m1.8b2.7b823.0m

Inventories

(437.0m)(987.0m)(838.0m)(537.0m)(542.0m)(471.0m)(554.0m)

Cash From Operating Activities

715.0m2.0b4.1b2.6b4.8b7.5b2.1b
USDFY, 2010

Debt/Equity

0.6 x

Debt/Assets

0.2 x

Financial Leverage

2.6 x
Show all financial metrics

Abbott Operating Metrics

FY, 2019FY, 2020FY, 2021

Products

1.5 k

Manufacturing Sites

929390

Manufacturing Sites (Cardiovascular and Neuromodulation Products)

272727

Manufacturing Sites (Diagnostic Products)

232424

Abbott Acquisitions / Subsidiaries

Company NameDateDeal Size
Walk VascularSeptember 02, 2021
Cephea Valve TechnologiesJanuary 16, 2019
St. Jude MedicalApril 28, 2016$25 b
Kalila MedicalApril 06, 2016
AlereFebruary 02, 2016$5.3 b
Tendyne HoldingsJuly 31, 2015$250 m
VeropharmDecember 12, 2014$305 m
ToperaOctober 29, 2014$250 m
CFR PharmaceuticalsMay 15, 2014$2.9 b
IDEV TechnologiesJuly 15, 2013$310 m
Show more

Abbott Revenue Breakdown

Embed Graph

Abbott revenue breakdown by business segment: 36.3% from Diagnostics, 33.4% from Medical Devices, 19.3% from Nutritionals, 11.0% from Established Pharmaceuticals and 0.1% from Other

Abbott revenue breakdown by geographic segment: 38.6% from United States and 61.4% from International

Abbott Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Abbott Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Abbott Online and Social Media Presence

Embed Graph

Abbott Company Culture

  • Overall Culture

    B+

    73/100

  • CEO Rating

    A+

    80/100

  • Compensation

    B

    72/100

  • Diversity

    B+

    73/100

Learn more on Comparably

Abbott News and Updates

Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

Sales growth of 10.1 percent; organic sales growth of 14.3 percent GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent Global COVID-19 testing-related sales of $2.3 billion in the second quarter Continues to strengthen portfolio with new product approvals...

Abbott Declares 394th Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 10, 2022 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 47 cents per share. This marks the 394th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2022,...

Late-Breaking Data Reinforce Broad Range of Patients Benefit from Abbott's Mitral and Tricuspid Heart Valve Devices

- New results demonstrate MitraClip™ transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR)

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System

Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System Content Import Fri, 06/03/2022 - 09:00 Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System June 3, 2022 at 9:00 AM EDT General Abbott i…
Show more

Abbott Blogs

Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes

- Abbott is committing $5 million over three years to the American Diabetes Association (ADA) to help close the health disparities gap for underserved diabetes communities, especially people of color and lower-income Americans

Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)

- Abbott achieves top industry scores in governance/economic and social performance, earns more than triple the average industry score in its industry sector

Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain

-- Radiofrequency ablation is a minimally invasive procedure to deactivate nerves associated with pain for up to one year

Abbott Introduces Next-generation 3D Cardiac Mapping Platform in Europe and Australia

- The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures

Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device

-- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020   -- The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people
Show more

Abbott Frequently Asked Questions

  • When was Abbott founded?

    Abbott was founded in 1888.

  • Who are Abbott key executives?

    Abbott's key executives are Robert B. Ford, Robert E. Funck and Hubert L. Allen.

  • How many employees does Abbott have?

    Abbott has 113,000 employees.

  • What is Abbott revenue?

    Latest Abbott annual revenue is $43.1 b.

  • What is Abbott revenue per employee?

    Latest Abbott revenue per employee is $381.2 k.

  • Who are Abbott competitors?

    Competitors of Abbott include Danaher, Thermo Fisher Scientific and Otricath.

  • Where is Abbott headquarters?

    Abbott headquarters is located at 100 Abbott Park Rd, Lake Bluff.

  • Where are Abbott offices?

    Abbott has offices in Lake Bluff, Alameda, Austin, Des Plaines and in 126 other locations.

  • How many offices does Abbott have?

    Abbott has 145 offices.